Physician profile
Millie Fell
NPI 1780607192
$2,914.17
in general payments reported to CMS, 2019-2025
26 companies · $454 in 2025
The $454 reported for 2025 was more than what 77% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $103 · 2020: $107 · 2021: $400 · 2022: $624 · 2023: $616 · 2024: $610 · 2025: $454.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,681.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,680.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $435.20 | 2020-2025 | Rocklatan, Eysuvis, Tryptyr |
| Regeneron Healthcare Solutions, INC. | $388.69 | 2021-2025 | Eylea Hd, Eylea |
| Mallinckrodt Hospital Products INC. | $264.90 | 2021-2024 | Acthar |
| Sun Pharmaceutical Industries INC. | $256.41 | 2021-2025 | Cequa |
| Tarsus Pharmaceuticals, INC. | $196.04 | 2024-2025 | Xdemvy |
| Allergan, INC. | $164.09 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $121.80 | 2022-2025 | Vyzulta, Envista Mx60 Iol, Amvisc Plus |
| Thea Pharma INC. | $119.74 | 2023-2025 | Iyuzeh |
| Dompe US, INC. | $109.15 | 2022-2025 | Oxervate |
| Oyster Point Pharma, INC. | $92.15 | 2022-2024 | Tyrvaya |
| Apellis Pharmaceuticals, INC. | $88.94 | 2023-2024 | Syfovre |
| Aerie Pharmaceuticals, INC. | $88.56 | 2019-2021 | |
| Genentech USA, INC. | $69.74 | 2022-2023 | Vabysmo |
| Akorn Operating Company LLC | $63.37 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $54.30 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $50.57 | 2023-2025 | |
| Biotissue Holdings INC. | $48.47 | 2023-2024 | |
| Eyevance Pharmaceuticals LLC | $48.34 | 2022 | |
| Harrow Eye, LLC | $47.03 | 2024 | Vevye |
| Kala Pharmaceuticals, INC. | $44.91 | 2019 | |
| Novartis Pharmaceuticals Corporation | $38.12 | 2020-2022 | |
| Sight Sciences, INC. | $29.80 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $28.36 | 2021 | |
| Rayner Intraocular Lenses Limited | $25.35 | 2023 | Rayone Emv, Rayone Spheric, Rayone Aspheric |
| Horizon Therapeutics Plc | $20.74 | 2022 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Millie Fell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.